1
TITLE: Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT) : a randomised, double-blind, placebo-controlled, phase 2 study  Full Text
AUTHORS: Wainberg, Zev A.; Enzinger, Peter C.; Kang, Yoon Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A.; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeno; Collins, Helen; Mitra, Siddhartha; Yang, Yingsi; Catenacci, Daniel V. T.; Lee, Keun Wook; ...More
PUBLISHED: 2022, SOURCE: LANCET ONCOLOGY, VOLUME: 23, ISSUE: 11
INDEXED IN: Scopus WOS
2
TITLE: A new anti-mesothelin antibody targets selectively the membrane-associated form
AUTHORS: Kamal Asgarov; Jeremy Balland; Charline Tirole; Adeline Bouard; Virginie Mougey; Diana Ramos; Antonio Barroso; Vincent Zangiacomi; Marine Jary; Stefano Kim; Maria Gonzalez Pajuelo; Bernard Royer; Hans de Haard; Andy Clark; John Wijdenes; Christophe Borg;
PUBLISHED: 2017, SOURCE: MABS, VOLUME: 9, ISSUE: 3
INDEXED IN: Scopus WOS